FDA Grants Priority Review to Pembrolizumab Monotherapy for TMB-High Tumors

The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news